Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insider Cintia Piccina Sells 24,531 Shares (2024)

Posted by Defense World Staff on Jun 19th, 2024

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) insider Cintia Piccina sold 24,531 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $0.93, for a total value of $22,813.83. Following the sale, the insider now directly owns 38,293 shares of the company’s stock, valued at $35,612.49. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Adaptimmune Therapeutics Stock Performance

ADAP opened at $0.88 on Wednesday. Adaptimmune Therapeutics plc has a fifty-two week low of $0.42 and a fifty-two week high of $2.05. The company has a market capitalization of $217.20 million, a P/E ratio of -1.19 and a beta of 2.34. The stock has a fifty day moving average of $1.08 and a 200-day moving average of $1.08.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last posted its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Adaptimmune Therapeutics had a negative return on equity of 259.68% and a negative net margin of 890.13%. The firm had revenue of $5.68 million for the quarter, compared to analyst estimates of $4.40 million. On average, equities research analysts predict that Adaptimmune Therapeutics plc will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Columbia Advisory Partners LLC acquired a new stake in shares of Adaptimmune Therapeutics during the first quarter worth $25,000. JTC Employer Solutions Trustee Ltd bought a new position in shares of Adaptimmune Therapeutics in the first quarter worth $41,000. Twin Focus Capital Partners LLC bought a new position in shares of Adaptimmune Therapeutics in the fourth quarter worth $44,000. Harbor Capital Advisors Inc. increased its position in shares of Adaptimmune Therapeutics by 9.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 13,317 shares during the period. Finally, Boulder Hill Capital Management LP bought a new position in shares of Adaptimmune Therapeutics in the first quarter worth $143,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ADAP shares. Mizuho decreased their price target on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, May 17th. Scotiabank started coverage on shares of Adaptimmune Therapeutics in a research note on Thursday, May 30th. They set a “sector outperform” rating and a $3.15 price target for the company. Finally, StockNews.com raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd.

View Our Latest Research Report on ADAP